Radiofrequency Ablation of Pancreatic Cancer

Alessandro Sarno; Alessandro Beleù; Riccardo De Robertis; Gabriele Giannotti; Giorgia Tedesco; Salvatore Paiella; Mirko D'Onofrio

doi:10.1055/s-0039-1688437

Digestive Disease Interventions, Inhaltsverzeichnis

Digestive Disease Interventions 2019; 03(02): 133-137
DOI: 10.1055/s-0039-1688437

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA

Radiofrequency Ablation of Pancreatic Cancer

Alessandro Sarno

¹Department of Radiology, G.B. Rossi Hospital, University of Verona, Verona, Italy

,

Alessandro Beleù

¹Department of Radiology, G.B. Rossi Hospital, University of Verona, Verona, Italy

,

Riccardo De Robertis

²Department of Radiology, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy

,

Gabriele Giannotti

¹Department of Radiology, G.B. Rossi Hospital, University of Verona, Verona, Italy

,

Giorgia Tedesco

¹Department of Radiology, G.B. Rossi Hospital, University of Verona, Verona, Italy

,

Salvatore Paiella

³Department of Surgery, G.B. Rossi Hospital, University of Verona, Verona, Italy

,

Mirko D'Onofrio

¹Department of Radiology, G.B. Rossi Hospital, University of Verona, Verona, Italy

› Institutsangaben

Abstract

Radiofrequency ablation (RFA) is emerging as a safe and feasible technique to treat various pancreatic lesions. In particular, pancreatic ductal adenocarcinoma (PDAC) is the most frequent treated lesion. Nowadays, PDAC treatment by means of RFA is limited to locally advanced, non-resectable, but non-metastatic lesions. The aim of this article is to describe the RFA technique, its results and possible complications.

Keywords

pancreas - radiofrequency ablation - pancreatic adenocarcinoma

Volltext

Referenzen

References
1 Goldberg SN, Grassi CJ, Cardella JF. , et al; Society of Interventional Radiology Technology Assessment Committee and the International Working Group on Image-guided Tumor Ablation. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol 2009; 20 (7, Suppl): S377-S390
2 McWilliams JP, Lee EW, Yamamoto S, Loh CT, Kee ST. Image-guided tumor ablation: emerging technologies and future directions. Semin Intervent Radiol 2010; 27 (03) 302-313
3 Goldberg SN, Mallery S, Gazelle GS, Brugge WR. EUS-guided radiofrequency ablation in the pancreas: results in a porcine model. Gastrointest Endosc 1999; 50 (03) 392-401
4 Girelli R, Frigerio I, Salvia R, Barbi E, Tinazzi Martini P, Bassi C. Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Br J Surg 2010; 97 (02) 220-225
5 Giardino A, Girelli R, Frigerio I. , et al. Triple approach strategy for patients with locally advanced pancreatic carcinoma. HPB (Oxford) 2013; 15 (08) 623-627
6 Paiella S, Malleo G, Cataldo I. , et al. Radiofrequency ablation for locally advanced pancreatic cancer: SMAD4 analysis segregates a responsive subgroup of patients. Langenbecks Arch Surg 2018; 403 (02) 213-220
7 Choi JH, Seo DW, Song TJ. , et al. Endoscopic ultrasound-guided radiofrequency ablation for management of benign solid pancreatic tumors. Endoscopy 2018; 50 (11) 1099-1104
8 Spiliotis JD, Datsis AC, Michalopoulos NV. , et al. Radiofrequency ablation combined with palliative surgery may prolong survival of patients with advanced cancer of the pancreas. Langenbecks Arch Surg 2007; 392 (01) 55-60
9 D'Onofrio M, Ciaravino V, De Robertis R. , et al. Percutaneous ablation of pancreatic cancer. World J Gastroenterol 2016; 22 (44) 9661-9673
10 Tempero MA, Malafa MP, Al-Hawary M. , et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2017; 15 (08) 1028-1061
11 Carrafiello G, Laganà D, Recaldini C. , et al. Radiofrequency ablation of a pancreatic metastasis from renal cell carcinoma: case report. Surg Laparosc Endosc Percutan Tech 2008; 18 (01) 64-66
12 Rossi S, Viera FT, Ghittoni G. , et al. Radiofrequency ablation of pancreatic neuroendocrine tumors: a pilot study of feasibility, efficacy, and safety. Pancreas 2014; 43 (06) 938-945
13 Kim YS, Rhim H, Lim HK, Choi D, Lee MW, Park MJ. Coagulation necrosis induced by radiofrequency ablation in the liver: histopathologic and radiologic review of usual to extremely rare changes. Radiographics 2011; 31 (02) 377-390
14 Dromi SA, Walsh MP, Herby S. , et al. Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity. Radiology 2009; 251 (01) 58-66
15 Teng LS, Jin KT, Han N, Cao J. Radiofrequency ablation, heat shock protein 70 and potential anti-tumor immunity in hepatic and pancreatic cancers: a minireview. Hepatobiliary Pancreat Dis Int 2010; 9 (04) 361-365
16 D'Onofrio M, Barbi E, Girelli R. , et al. Radiofrequency ablation of locally advanced pancreatic adenocarcinoma: an overview. World J Gastroenterol 2010; 16 (28) 3478-3483
17 Shah R, Ostapoff KT, Kuvshinoff B, Hochwald SN. Ablative therapies for locally advanced pancreatic cancer. Pancreas 2018; 47 (01) 6-11
18 Pai M, Habib N, Senturk H. , et al. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors. World J Gastrointest Surg 2015; 7 (04) 52-59
19 Arcidiacono PG, Carrara S, Reni M. , et al. Feasibility and safety of EUS-guided cryothermal ablation in patients with locally advanced pancreatic cancer. Gastrointest Endosc 2012; 76 (06) 1142-1151
20 Pai M, Yang J, Zhang X. , et al. PWE-055 endoscopic ultrasound guided radiofrequency ablation (EUS-RFA) for pancreatic ductal adenocarcinoma. Gut 2013; 62 (Suppl. 01) A153
21 Cantore M, Girelli R, Mambrini A. , et al. Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma. Br J Surg 2012; 99 (08) 1083-1088
22 D'Onofrio M, Crosara S, De Robertis R. , et al. Percutaneous radiofrequency ablation of unresectable locally advanced pancreatic cancer: preliminary results. Technol Cancer Res Treat 2017; 16 (03) 285-294
23 Elias D, Baton O, Sideris L, Lasser P, Pocard M. Necrotizing pancreatitis after radiofrequency destruction of pancreatic tumours. Eur J Surg Oncol 2004; 30 (01) 85-87
24 Ruarus A, Vroomen L, Puijk R, Scheffer H, Meijerink M. Locally advanced pancreatic cancer: a review of local ablative therapies. Cancers (Basel) 2018; 10 (01) E16
25 D'Onofrio M, Barbi E, Girelli R. , et al. Variation of tumoral marker after radiofrequency ablation of pancreatic adenocarcinoma. J Gastrointest Oncol 2016; 7 (02) 213-220
26 Lorentzen T. A cooled needle electrode for radiofrequency tissue ablation: thermodynamic aspects of improved performance compared with conventional needle design. Acad Radiol 1996; 3 (07) 556-563
27 McDermott S, Gervais DA. Radiofrequency ablation of liver tumors. Semin Intervent Radiol 2013; 30 (01) 49-55
28 Wu Y, Tang Z, Fang H. , et al. High operative risk of cool-tip radiofrequency ablation for unresectable pancreatic head cancer. J Surg Oncol 2006; 94 (05) 392-395
29 Matsui Y, Nakagawa A, Kamiyama Y, Yamamoto K, Kubo N, Nakase Y. Selective thermocoagulation of unresectable pancreatic cancers by using radiofrequency capacitive heating. Pancreas 2000; 20 (01) 14-20
30 Hadjicostas P, Malakounides N, Varianos C, Kitiris E, Lerni F, Symeonides P. Radiofrequency ablation in pancreatic cancer. HPB (Oxford) 2006; 8 (01) 61-64
31 Rombouts SJ, Vogel JA, van Santvoort HC. , et al. Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer. Br J Surg 2015; 102 (03) 182-193
32 Paiella S, Salvia R, Ramera M. , et al. Local ablative strategies for ductal pancreatic cancer (radiofrequency ablation, irreversible electroporation): a review. Gastroenterol Res Pract 2016; 2016: 4508376
33 Keane MG, Bramis K, Pereira SP, Fusai GK. Systematic review of novel ablative methods in locally advanced pancreatic cancer. World J Gastroenterol 2014; 20 (09) 2267-2278
34 Pandya GJ, Shelat VG. Radiofrequency ablation of pancreatic ductal adenocarcinoma: The past, the present and the future. World J Gastrointest Oncol 2015; 7 (02) 6-11
35 Verslype C, Van Cutsem E, Dicato M. , et al. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on gastrointestinal cancer, Barcelona, 2006. Ann Oncol 2007; 18 (Suppl. 07) vii1-vii10
36 Von Hoff DD, Ervin T, Arena FP. , et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369 (18) 1691-1703
37 Conroy T, Desseigne F, Ychou M. , et al; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364 (19) 1817-1825
38 Takaori K, Bassi C, Biankin A. , et al; IAP/EPC study group on the clinical managements of pancreatic cancer. International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Pancreatology 2016; 16 (01) 14-27
39 Girelli R, Frigerio I, Giardino A. , et al. Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma. Langenbecks Arch Surg 2013; 398 (01) 63-69
40 Frigerio I, Girelli R, Giardino A, Regi P, Salvia R, Bassi C. Short term chemotherapy followed by radiofrequency ablation in stage III pancreatic cancer: results from a single center. J Hepatobiliary Pancreat Sci 2013; 20 (06) 574-577
41 Wu PH, Pan CC, Huang ZL, Li W, Zhao M, Zhou ZW. Percutaneous radiofrequency ablation approach through the spleen: initial case report for pancreatic tail gastrinoma. Chin J Cancer 2010; 29 (09) 836-841